Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Etelcalcetide
Drug ID BADD_D02514
Description Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017.
Indications and Usage Etelcalcetide is a calcium-sensing receptor agonist indicated for: Secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Marketing Status Not Available
ATC Code H05BX04
DrugBank ID DB12865
KEGG ID D10676
MeSH ID C583569
PubChem ID 71511839
TTD Drug ID D07RYI
NDC Product Code 55513-740; 55463-0030; 52076-6227; 55513-742; 55513-741
Synonyms etelcalcetide hydrochloride | velcalcetide | etelcalcetide | KAI-4169 | Parsabiv | AMG-416 | AMG 416
Chemical Information
Molecular Formula C38H73N21O10S2
CAS Registry Number 1262780-97-1
SMILES CC(C(=O)NC(CCCN=C(N)N)C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN= C(N)N)NC(=O)C(C)NC(=O)C(CSSCC(C(=O)O)N)NC(=O)C
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Gastrooesophageal reflux disease07.02.02.0030.007228%
Gastrointestinal disorder07.11.01.0010.045780%Not Available
Gastrointestinal haemorrhage24.07.02.009; 07.12.02.0010.040961%Not Available
Haematochezia24.07.02.012; 07.12.02.0030.004819%Not Available
Haemoglobin abnormal13.01.05.0110.007228%Not Available
Haemoglobin decreased13.01.05.0030.016866%Not Available
Hallucination19.10.02.002--
Headache17.14.01.001--
Heart rate increased13.14.04.0020.009638%Not Available
Hypercalcaemia14.04.01.003; 05.04.01.0020.009638%
Hyperhidrosis23.02.03.004; 08.01.03.028--
Hyperkalaemia14.05.03.0010.007228%
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.0230.024095%Not Available
Hypocalcaemia14.04.01.0040.139750%
Hypotension24.06.03.002--
Influenza11.05.03.001; 22.07.02.001--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.0330.007228%Not Available
Intestinal perforation07.04.06.0020.016866%Not Available
Laboratory test abnormal13.18.01.001--Not Available
Lethargy08.01.01.008; 19.04.04.004; 17.02.04.0030.014457%
Loss of consciousness17.02.04.004--Not Available
Malaise08.01.01.003--
Migraine24.03.05.003; 17.14.02.0010.016866%Not Available
Muscle spasms15.05.03.0040.053009%
Muscle twitching15.05.03.0050.021685%Not Available
Muscular weakness17.05.03.005; 15.05.06.0010.016866%
Musculoskeletal pain15.03.04.007--
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages